scholarly journals Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Oncotarget ◽  
2021 ◽  
Vol 12 (23) ◽  
pp. 2321-2322
Author(s):  
Manabu Seino ◽  
Tsuyoshi Ohta ◽  
Akiko Sugiyama ◽  
Hirotsugu Sakaki ◽  
Takeshi Sudo ◽  
...  
Keyword(s):  
Acquired Resistance ◽  
Serous Carcinoma ◽  
Metabolomic Analysis ◽  
Uterine Serous Carcinoma

scholarly journals Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Oncotarget ◽  
2018 ◽  
Vol 9 (62) ◽  
pp. 31985-31998 ◽  
Author(s):  
Manabu Seino ◽  
Tsuyoshi Ohta ◽  
Akiko Sugiyama ◽  
Hirotsugu Sakaki ◽  
Takeshi Sudo ◽  
...  
Keyword(s):  
Acquired Resistance ◽  
Serous Carcinoma ◽  
Metabolomic Analysis ◽  
Uterine Serous Carcinoma

Abstract 383: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

2018 ◽  
Author(s):  
Manabu Seino ◽  
Tsuyoshi Ohta ◽  
Hirotsugu Sakaki ◽  
Takeshi Sudo ◽  
Satoru Nagase
Keyword(s):  
Acquired Resistance ◽  
Serous Carcinoma ◽  
Metabolomic Analysis ◽  
Uterine Serous Carcinoma

scholarly journals Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

2015 ◽  
Vol 14 (11) ◽  
pp. 2519-2526 ◽  
Author(s):  
Salvatore Lopez ◽  
Emiliano Cocco ◽  
Jonathan Black ◽  
Stefania Bellone ◽  
Elena Bonazzoli ◽  
...  
Keyword(s):  
Cell Lines ◽  
Carcinoma Cell ◽  
Single Agent ◽  
Acquired Resistance ◽  
Serous Carcinoma ◽  
Carcinoma Cell Lines ◽  
Uterine Serous Carcinoma

scholarly journals Uterine serous carcinoma: key advances and novel treatment approaches

2021 ◽  
pp. ijgc-2021-002753
Author(s):  
J Stuart Ferriss ◽  
Britt K Erickson ◽  
Ie-Ming Shih ◽  
Amanda N Fader
Keyword(s):  
Endometrial Cancer ◽  
Black Women ◽  
Treatment Options ◽  
Molecular Genetic ◽  
Serous Carcinoma ◽  
Cancer Syndrome ◽  
Her2 Positive ◽  
Incidence And Mortality ◽  
History Of ◽  
Uterine Serous Carcinoma

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Clinical risk factors for uterine serous carcinoma include advancing age, a history of breast cancer, tamoxifen usage, and the hereditary breast–ovarian cancer syndrome. Surgery remains the cornerstone of treatment. Recent advances in our understanding of uterine serous carcinoma molecular drivers have led to development of targeted therapeutics that promise improved outcomes for patients. Overexpression or amplification of HER2 in uterine serous carcinoma carries a poor prognosis; yet this actionable target has led to the incorporation of several anti-HER2 therapies, including trastuzumab which, when added to conventional chemotherapy, is associated with improved survival for women with advanced and recurrent HER2-positive disease. The combination of pembrolizumab and lenvatinib is also a promising targeted treatment strategy for women with uterine serous carcinoma, with a recent phase II study suggesting a 50% response rate in women with recurrent disease. Several trials examining additional targeted agents are ongoing. Despite years of stalled progress, meaningful, tailored treatment options are emerging for patients with this uncommon and biologically aggressive endometrial cancer subtype.

scholarly journals Pineal gland metastasis from uterine serous carcinoma: A case report and review of the literature

2021 ◽  
pp. 100738
Author(s):  
Samantha Carson ◽  
Kristopher G. Hooten ◽  
Kristen P. Bunch
Keyword(s):  
Case Report ◽  
Pineal Gland ◽  
Serous Carcinoma ◽  
Review Of The Literature ◽  
Uterine Serous Carcinoma

Is platinum-free interval relevant in recurrent uterine serous carcinoma?

2020 ◽  
Vol 159 ◽  
pp. 205-206
Author(s):  
R.N. Beavers ◽  
B. Fellman ◽  
M. Eyada ◽  
A.H. Klopp ◽  
N.D. Fleming ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Free Interval ◽  
Uterine Serous Carcinoma

The impact of age and stage on the competing risk of cancer-related and non-cancer death in low- or high-grade endometrioid endometrial carcinoma and uterine serous carcinoma

2021 ◽  
Vol 162 ◽  
pp. S293-S294
Author(s):  
Cassandra Presti ◽  
Chunqiao Tian ◽  
Emma Robinson ◽  
Tahimi Gonzalez ◽  
Chad Hamilton ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Competing Risk ◽  
Serous Carcinoma ◽  
High Grade ◽  
Cancer Death ◽  
Uterine Serous Carcinoma ◽  
Endometrioid Endometrial Carcinoma ◽  
Risk Of Cancer ◽  
The Impact

Uterine serous carcinoma: a comparison of therapy for advanced-stage disease

2004 ◽  
Vol 14 (3) ◽  
pp. 515-520 ◽  
Author(s):  
P. A. Gehrig ◽  
D. E. Morris ◽  
L. Van Le
Keyword(s):  
Serous Carcinoma ◽  
Advanced Stage ◽  
Stage Disease ◽  
Uterine Serous Carcinoma
Sign in / Sign up

Export Citation Format

Share Document